Suppr超能文献

宿主来源的基质金属蛋白酶-13 活性促进多发性骨髓瘤诱导的溶骨性骨病,并降低总生存期。

Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.

机构信息

Department of Tumor Biology, University of South Florida, Tampa, Florida.

Cancer Biology Ph.D. Program, Department of Cell Biology Microbiology and Molecular Biology, University of South Florida, Tampa, Florida.

出版信息

Cancer Res. 2021 May 1;81(9):2415-2428. doi: 10.1158/0008-5472.CAN-20-2705. Epub 2021 Feb 1.

Abstract

Multiple myeloma promotes systemic skeletal bone disease that greatly contributes to patient morbidity. Resorption of type I collagen-rich bone matrix by activated osteoclasts results in the release of sequestered growth factors that can drive progression of the disease. Matrix metalloproteinase-13 (MMP13) is a collagenase expressed predominantly in the skeleton by mesenchymal stromal cells (MSC) and MSC-derived osteoblasts. Histochemical analysis of human multiple myeloma specimens also demonstrated that MMP13 largely localizes to the stromal compartment compared with CD138 myeloma cells. In this study, we further identified that multiple myeloma induces MMP13 expression in bone stromal cells. Because of its ability to degrade type I collagen, we examined whether bone stromal-derived MMP13 contributed to myeloma progression. Multiple myeloma cells were inoculated into wild-type or MMP13-null mice. In independent studies, MMP13-null mice demonstrated significantly higher overall survival rates and lower levels of bone destruction compared with wild-type controls. Unexpectedly, no differences in type I collagen processing between the groups were observed. stromal coculture assays showed reduced formation and activity in MMP13-null osteoclasts. Analysis of soluble factors from wild-type and MMP13-null MSCs revealed decreased bioavailability of various osteoclastogenic factors including CXCL7. CXCL7 was identified as a novel MMP13 substrate and regulator of osteoclastogenesis. Underscoring the importance of host MMP13 catalytic activity in multiple myeloma progression, we demonstrate the efficacy of a novel and highly selective MMP13 inhibitor that provides a translational opportunity for the treatment of this incurable disease. SIGNIFICANCE: Genetic and pharmacologic approaches show that bone stromal-derived MMP13 catalytic activity is critical for osteoclastogenesis, bone destruction, and disease progression. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/9/2415/F1.large.jpg.

摘要

多发性骨髓瘤会导致全身性骨骼疾病,极大地增加了患者的发病率。破骨细胞对富含 I 型胶原蛋白的骨基质的吸收会导致被隔离的生长因子的释放,这些因子可以驱动疾病的进展。基质金属蛋白酶 13(MMP13)是一种主要由间充质基质细胞(MSC)和 MSC 衍生的成骨细胞在骨骼中表达的胶原酶。对人类多发性骨髓瘤标本的组织化学分析还表明,与 CD138 骨髓瘤细胞相比,MMP13 主要定位于基质区室。在这项研究中,我们进一步确定多发性骨髓瘤可诱导骨基质细胞表达 MMP13。由于其降解 I 型胶原蛋白的能力,我们研究了骨基质衍生的 MMP13 是否有助于骨髓瘤的进展。将骨髓瘤细胞接种到野生型或 MMP13 缺失型小鼠中。在独立的研究中,与野生型对照组相比,MMP13 缺失型小鼠的总生存率显著提高,骨破坏程度较低。出乎意料的是,两组之间未观察到 I 型胶原蛋白处理的差异。基质共培养实验显示 MMP13 缺失型破骨细胞的形成和活性降低。对野生型和 MMP13 缺失型 MSC 释放的可溶性因子进行分析,发现各种破骨细胞生成因子(包括 CXCL7)的生物利用度降低。CXCL7 被鉴定为 MMP13 的一种新型底物和破骨细胞生成的调节剂。鉴于宿主 MMP13 催化活性在多发性骨髓瘤进展中的重要性,我们证明了一种新型高选择性 MMP13 抑制剂的疗效,为治疗这种无法治愈的疾病提供了转化机会。意义:遗传和药物方法表明,骨基质衍生的 MMP13 催化活性对于破骨细胞生成、骨破坏和疾病进展至关重要。

相似文献

引用本文的文献

5
Redefining metalloproteases specificity through network proteolysis.通过网络蛋白水解重新定义金属蛋白酶的特异性。
Trends Mol Med. 2024 Feb;30(2):147-163. doi: 10.1016/j.molmed.2023.11.001. Epub 2023 Nov 29.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验